KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash from Investing Activities: 2010-2025

Historic Cash from Investing Activities for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -$94.9 million.

  • Nektar Therapeutics' Cash from Investing Activities fell 305.73% to -$94.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.6 million, marking a year-over-year decrease of 41.20%. This contributed to the annual value of $142.6 million for FY2024, which is 2.15% up from last year.
  • Latest data reveals that Nektar Therapeutics reported Cash from Investing Activities of -$94.9 million as of Q3 2025, which was down 291.22% from $49.6 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Cash from Investing Activities high stood at $130.3 million for Q1 2022, and its period low was -$94.9 million during Q3 2025.
  • For the 3-year period, Nektar Therapeutics' Cash from Investing Activities averaged around $25.5 million, with its median value being $40.6 million (2023).
  • Per our database at Business Quant, Nektar Therapeutics' Cash from Investing Activities surged by 13,521.08% in 2022 and then tumbled by 305.73% in 2025.
  • Nektar Therapeutics' Cash from Investing Activities (Quarterly) stood at $120.2 million in 2021, then crashed by 66.71% to $40.0 million in 2022, then plummeted by 56.56% to $17.4 million in 2023, then spiked by 246.40% to $60.2 million in 2024, then plummeted by 305.73% to -$94.9 million in 2025.
  • Its Cash from Investing Activities stands at -$94.9 million for Q3 2025, versus $49.6 million for Q2 2025 and $43.7 million for Q1 2025.